Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 2255-2269

  Denora, Nunzio ^a   Laquintana, Valentino ^a   Trapani, Adriana ^a   Lopedota, Angela ^a   Latrofa, Andrea ^a   Gallo, James M ^b   Trapani, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL]ACETAMIDE; 2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL]ACETAMIDE; 2 [6,8 DICHLORO 2 (PHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL]ACETAMIDE; 4 [6,8 DICHLORO 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZO[1,2 A]PYRIDIN 2 YL]PHENYL 1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YLCARBAMATE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYTARABINE; CYTIDINE DEAMINASE; DIAZEPAM; GLYCOPROTEIN P; IMIDAZOPYRIDINE DERIVATIVE; N IMIDAZOPYRIDINACETYLCYTARABINE CONJUGATE; N1 [2 (4 CHLOROPHENYL) 3 [2 (DIPROPYLAMINO) 2 OXOETHYL]IMIDAZO[1,2 A]PYRIDIN 8 YL] N6 [1 [3,4 DIHYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL]ADIPAMIDE; NUCLEOSIDE TRANSPORTER; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL STRAIN; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVATION; ENZYME STABILITY; FEMALE; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROLYSIS; LIPOPHILICITY; MALE; MASS SPECTROMETRY; MELTING POINT; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACETAMIDES; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PYRIDINES; STEREOISOMERISM;

EID: 78649910298     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100235w     Document Type: Article

References (47)

1. Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapère, J. J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M. R.; Gavish, M. Translocator Protein (18 kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function Trends Pharmacol. Sci. 2006, 27, 402-409
2. Anholt, R. R. H.; Pedersen, P. L.; De Souza, E. B.; Snyder, S. H. The peripheral benzodiazepine receptor: localization to the mitochondrial outer membrane J. Biol. Chem. 1986, 261, 576-583
3. Veenman, L.; Levin, E.; Weisinger, G.; Leschiner, S.; Spanier, I.; Snyder, S. H.; Weizman, A.; Gavish, M. Peripheral-type benzodiazepine receptor density and in vitro tumorogenicity of glioma cell lines Biochem. Pharmacol. 2004, 68, 689-698
4. Galiegue, S.; Tinel, N.; Casellas, P. The peripheral benzodiazepine receptors: a promising therapeutic drug target Curr. Med. Chem. 2003, 10, 1563-1572
5. Papadopulos, V.; Guarneri, P.; Krueger, K. E.; Guidotti, A.; Costa, E. Pregnenolone biosynthesis in C6 glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5113-5117
6. Messmer, K.; Reynolds, G. P. Increased peripheral benzodiazepine binding site in the brain of patients with Huntington's disease Neurosci. Lett. 1998, 241, 53-56
7. Veenman, L.; Gavish, M. Peripheral-type benzodiazepine receptors: their implication in brain disease Drug Dev. Res. 2000, 50, 355-370
8. Maaser, K.; Grabowski, P.; Surter, A. P.; Hopfner, M.; Foss, H. D.; Stein, H.; Berger, G.; Gavish, M.; Zeitz, M.; Scherübl, A. P. Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer Clin. Cancer Res. 2002, 8, 3205-3209
9. Hardwick, M.; Fertikh, D.; Culty, M.; Li, H.; Vidic, B.; Papadopoulos, V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: Correlation of breast cancer cell aggressive phenotype with PBR espression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol Cancer Res. 1999, 59, 831-842
10. Katz, Y.; Eitan, A.; Gavish, M. Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumors and normal ovaries Clin. Sci. 1990, 78, 155-158
11. Venturini, I.; Zaneroli, M. L.; Corsi, L.; Avallona, R.; Farina, F.; Alho, H.; Baraldi, C.; Ferrarese, C.; Pecora, N.; Frigo, M.; Ardizzone, G.; Arrigo, A.; Pellicci, R.; Baraldi, M. Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma Life Sci. 1998, 65, 1269-1280
12. Hirsch, T.; Decaudin, D.; Susin, S. A.; Marchetti, P.; Larochette, N.; Resche-Rigon, M.; Kroemer, G. PK 11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2 mediated cytoprotection Exp. Cell. Res. 1998, 241, 426-434
13. Sutter, A. P.; Maaser, K.; Barthel, B.; Scherübl, H. Ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in oesophageal cancer cells: involvement of the p38mapk signalling pathway Br. J. Cancer 2003, 89, 564-572
14. Xia, W.; Spector, S.; Hardy, L.; Zhao, S.; Saluk, A.; Alemane, L.; Spector, N. L. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7494-7499
15. Maaser, K.; Hopfner, M.; Jansen, A.; Weisinger, G.; Gavish, M.; Kozikowski, A. P.; Weizman, A.; Carayon, P.; Riecken, E. O.; Zeitz, M.; Scherübl, H. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells Br. J. Cancer 2001, 85, 1771-1780
16. Romeo, E.; Auta, J.; Kozikowski, A. P.; Ma, A.; Papadopoulos, V.; Puia, G.; Costa, E.; Guidotti, A. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor J. Pharmacol. Exp. Ther. 1992, 262, 971-978
17. Le Fur, G.; Perrier, M. L.; Vaucher, N.; Imbault, F.; Flamier, A.; Uzan, A.; Renault, C.; Dubroeucq, M. C.; Gueremy, C. Peripheral benzodiazepine binding sites: effect of PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide: I. In vitro studies Life Sci. 1983, 32, 1839-1847 (Pubitemid 13079423)
18. 3H]Ro 5-4864 Mol. Pharmacol. 1982, 22, 26-32
19. Okujama, S.; Chaki, S.; Yoshikawa, R.; Ogawa, S.; Suzuki, Y.; Okubo, T.; Nakazato, A.; Nagamine, M.; Tomisawa, K. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106 Life Sci. 1999, 16, 1455-1464
20. Laquintana, V.; Denora, N.; Musacchio, T.; Lasorsa, M.; Latrofa, A.; Trapani, G. Peripheral benzodiazepine receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents J. Controlled Release 2009, 137, 185-195
21. Trapani, G.; Laquintana, V.; Denora, N.; Trapani, A.; Lopedota, A.; Latrofa, A.; Franco, M.; Serra, M.; Pisu, M. G.; Floris, I.; Sanna, E.; Biggio, G.; Liso, G. Structure-activity relationships and effects on neuroactive steroids in a series of 2-phenylimidazo-[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands J. Med. Chem. 2005, 48, 292-305
22. Denora, N.; Laquintana, V.; Pisu, M. G.; Dore, R.; Murru, L.; Latrofa, A.; Trapani, G.; Sanna, E. 2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies J. Med. Chem. 2008, 51, 6876-6888
23. Laquintana, V.; Trapani, A.; Denora, N.; Wang, F.; Gallo, J. M.; Trapani, G. New strategies to deliver anticancer drugs to brain tumors Expert Opin. Drug Delivery 2009, 6, 1017-1032
24. Guo, P.; Ma, J.; Li, S.; Guo, Z.; Adams, A. L.; Gallo, J. M. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model Cancer Chemother. Pharmacol. 2001, 48, 169-176
25. Black, K. L.; Ikezaki, K.; Toga, A. W. Imaging of brain tumors using peripheral benzodiazepine receptor ligands J. Neurosurg. 1989, 71, 113-118
26. Black, K. L.; Ikezaki, K.; Santori, E.; Becker, D. P.; Vinters, H. V. Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man Cancer 1990, 65, 93-97
27. Harivardhan Reddy, L.; Couvreur, P. Novel approaches to deliver gemcitabine to cancers Curr. Pharm. Des. 2008, 14, 1124-1137
28. Kupczyk-Subotkowaka, L.; Siahaan, T. J.; Basile, A.; Friedman, H. S.; Higgins, P. E.; Song, D.; Gallo, J. M. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate J. Med. Chem. 1997, 40, 1726-1730
29. Trapani, G.; Laquintana, V.; Latrofa, A.; Ma, J.; Reed, K.; Serra, M.; Biggio, G.; Liso, G.; Gallo, J. M. Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors Bioconjugate Chem. 2003, 14, 830-839
30. Sun, Y.; Sun, J.; Shi, S.; Jing, Y.; Yin, S.; Chen, Y.; Li, G.; Xu, Y.; He, Z. Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-β- d -arabinofuranosylcytosine Mol. Pharmaceutics 2009, 6, 315-325
31. Kripp, M.; Hofheinz, R. D. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine Int. J. Nanomed. 2008, 3, 397-401
32. Benesch, M.; Siegler, N.; Hoff, K. V.; Lassay, L.; Kropshofer, G.; Müller, H.; Sommer, C.; Rutkowski, S.; Fleischhack, G.; Urban, C. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study Anti-Cancer Drugs 2009, 20, 794-799
33. Galmarini, C. M.; Myhren, F.; Sandvold, M. L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines Br. J. Haematol. 2008, 144, 263-275
34. Schiavon, O.; Pasut, G.; Moro, S.; Orsoline, P.; Guiotto, A.; Veronese, F. M. PEG-Ara-C conjugates for controlled release Eur. J. Med. Chem. 2004, 39, 123-133
35. Wipf, P.; Li, W. Prodrugs of Ara-C Drug Future 1994, 19, 49-54
36. Choe, Y. H.; Conover, C. D.; Wu, D.; Royzen, M.; Greenwald, R. B. Anticancer drug delivery systems: N 4-acyl poly(ethyleneglycol) prodrug of Ara-C I. Efficacy in solid tumors J. Controlled Release 2002, 79, 41-53
37. Sun., Y.; Sun, J.; Shi, S.; Jing, Y.; Yin, S.; Chen, Y.; Li, G.; Xu, Y.; He, Z. Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-b-D-arabinofuranosylcytosine Mol. Pharmaceutics 2009, 6, 315-325
38. Hansen, M.; Nielsen, S.; Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill Immunol. Methods 1989, 119, 203-210
39. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36, 268-275
40. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 1993, 53, 4595-4602
41. Denora, N.; Laquintana, V.; Lopedota, A.; Serra, M.; Dazzi, L.; Biggio, G.; Pal, D.; Mitra, A. K.; Latrofa, A.; Trapani, G.; Liso, G. Novel L-dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety Pharm. Res. 2007, 24, 1309-1324
42. Guo, Z.; Gallo, J. M. Selective protection of 2′,2′- difluorodeoxycytidine (Gemcitabine) J. Org. Chem. 1999, 64, 8319-8322
43. 11C]methyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro- 9H-purin-9-yl)acetamide Nucl. Med. Biol. 2009, 36, 801-809
44. Breistøl, K.; Balzarini, J.; Sandvold, M. L.; Myhren, F.; Martinsen, M.; De Clercq, E.; Fodstad, Ø Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models Cancer Res. 1999, 59, 2944-2949
45. Garberg, P.; Ball, M.; Borg, N.; Cecchelli, R.; Fenart, L.; Hurst, R. D.; Lindmark, T.; Mabondzo, A.; Nilsson, J. E.; Raub, T. J.; Stanimirovic, D.; Terasaki, T.; Öberg, J. O.; Österberg, T. In vitro models for the blood-brain barrier Toxicol. in Vitro 2005, 19, 299-334
46. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in silico methods for small molecule transfer across BBB J. Pharm. Sci. 2009, 98, 4429-4468
47. Colabufo, N. A.; Berardi, F.; Cantore, M.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials J. Med. Chem. 2010, 53, 1883-1897